US Stock MarketDetailed Quotes

EBS Emergent BioSolutions

Watchlist
  • 8.270
  • -0.150-1.78%
Close Dec 27 16:00 ET
  • 8.270
  • 0.0000.00%
Post 20:01 ET
448.10MMarket Cap-2.12P/E (TTM)

Emergent BioSolutions Key Stats

Emergent BioSolutions Q3 2024 Earnings Date

Currency:USDNov 6, 2024

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
Revenue
297.50M
293.80M
-3.70M
Miss Est.
+9.98%
+8.61%
-1.24%
EPS
-0.31
2.06
+2.37
Beat Est.
+93.82%
+140.55%
+756.05%
Buy

Nov 30, 2024

Emergent BioSolutions Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 248.000M--
Nov 6, 20242024/Q3293.800M / 297.500M--
Aug 6, 20242024/Q2254.700M / 190.000M--
May 1, 20242024/Q1300.400M / 220.250M--
Mar 6, 20242023/Q4276.600M / 274.000M--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 248.000M--
Nov 6, 20242024/Q3293.800M / 297.500M--
Aug 6, 20242024/Q2254.700M / 190.000M--
May 1, 20242024/Q1300.400M / 220.250M--
Mar 6, 20242023/Q4276.600M / 274.000M--

Unlock Free Earnings Estimates

Emergent BioSolutions Earnings Reports

Read more

Trending US Stocks
U.S Tech Companies U.S Tech Companies

U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Nov 30, 2024

Buy

  • Buy

    100.00%
  • Hold

    0.00%
  • Sell

    0.00%

Price Target

No Data